Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Japan BCG Faces Business Improvement Order over Manufacturing Methods
April 27, 2016
- MHLW Panel Supports Ono’s Cancer Drug Carfilzomib
April 26, 2016
- 13 New Countries Join Japan-EU Mutual Acceptance Scheme for GMP Data
April 26, 2016
- PMDA Reviewing Risk of Hep B Virus Reactivation for Sovaldi, Harvoni, Other Hep C Drugs
April 26, 2016
- PMDA Now Has 560 Full-Time Employees in Review Division
April 25, 2016
- Making PMDA World’s Most Trusted Regulatory Authority through “Regulatory Innovation”: Chief Executive
April 25, 2016
- Panel Eyes FY2017 Discussion Deadline for Prescribing Rules for Lifestyle Disease Drugs
April 22, 2016
- Giotrif Label to Add Acute Pancreatitis as Clinically Significant ADR
April 22, 2016
- Boehringer’s Triple Combo Hypertension Drug Put on Hold by MHLW Advisory Panel
April 21, 2016
- Key Govt Panel Launches Discussions on New Growth Strategy
April 20, 2016
- Opdivo’s Fulminant Type 1 Diabetes Risk Re-Stressed in MHLW Safety Bulletin
April 20, 2016
- LDP Finalizes Proposal for Growth Strategy; Touches on CIN, Drug Discovery Seeds
April 20, 2016
- Sales Reps Top Source of Drug Safety Information for Both Clinics and Pharmacies: PMDA Survey
April 19, 2016
- Wholesalers Cited Urgent Deliveries as Major Concern: Ryukaikon
April 19, 2016
- Wholesalers’ Negative Primary Margins on Sales Level Off: Ryukaikon
April 18, 2016
- PMDA Had 58 Paid Advisory Sessions on Drug Development for Startups, Academia: FY2015
April 18, 2016
- Ryukaikon Agrees on Mandatory Barcode Labeling by March 2021; March 2022 for Exceptions
April 18, 2016
- Quake Brings Production Offline at 1 Out of 24 Firms in Affected Region: MHLW
April 18, 2016
- Promoting Use of Patient Registries Important in Building Clinical Innovation Network: Health Policy Bureau Chief
April 18, 2016
- Dyslipidemia Risk Triples in Patients on Olanzapine: PMDA Epidemiology Study
April 15, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…